Abstract
Interferon synthesis is stimulated by a variety of factors including exposure to virus, antigen, or antibody and various mitogens. Three classes of interferon have been described and multiple subtypes identified. The use of interferon in clinical trials for the treatment of cancer and viral infections has been limited by the relatively low quantities of interferon available. Nonetheless, preliminary evidence suggests that human interferon has potent pharmacologic activity against at least some forms of cancer and viral infection. Extended clinical evaluation will be made possible by newly developed production processes, including the application of large scale biosynthesis and separation methodologies to interferon produced by human cells and the incorporation of human genes for interferons into simple, unicellular organisms.
- Received June 5, 1981.
- Accepted June 10, 1981.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.